Abstract:
Mogrosides containing non-glucose glycosides are provided herein. Compositions, including consumables comprising the novel mogrosides described herein, are also provided.
Abstract:
본 발명은 PPD(protopanaxadiol)류 진세노사이드 화합물이 처리된 세포를 사용하여 미토콘드리아 분열 조절제를 스크리닝하는 방법, 상기 PPD류 진세노사이드 화합물을 포함하는 미토콘드리아 분열 조절제 스크리닝용 조성물 및 상기 조성물을 포함하는 키트에 관한 것이다. 본 발명의 미토콘드리아 분열 조절제를 스크리닝하는 방법을 사용하면, 미토콘드리아의 분열을 조절하여 미토콘드리아 관련 질환을 예방, 개선 또는 치료할 수 있는 제제를 효과적으로 발굴할 수 있으므로, 미토콘드리아 관련 질환의 치료제 개발에 널리 활용될 수 있을 것이다.
Abstract:
The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs. This invention relates to a method for the production of a broad group of glycosylated drugs, including but not limited to propofol, acetaminophen, and camptothecin carbohydrate derivatives.
Abstract:
Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Abstract:
Provided is a method of purifying a macrolide, especially tacrolimus, that includes loading macrolide onto a bed of sorption resin and elting with a suitable eluent such as a combination of water and tetrahydrofuran.
Abstract:
The invention relates to the use of a composition comprising 10-90 wt. %, preferably 10-50 wt. %, more preferably 10-40 wt. % isostearyl glycoside having a degree of polymerization ranging from 1-3, and 90-10 % by weight, preferably 90-50 wt. %, more preferably 90-60 wt. % isostearyl alcohol, as an agent that improves the resistance of a cosmetic composition to water.
Abstract:
Inositolphosphoglycans (IPGs), and in particular A-type substances comprising myo-inositol, are tumour autocrine factors (TAFs), that is factors which cause tumour cell proliferation. The use of A-type IPG antagonists for the treatment of cancer and a method for the diagnosis or prognosis of cancer based on the presence or amount of IPGs in a sample from a patient is disclosed.
Abstract:
Praziquantel may be formulated to enhance its pharmacokinetic, toxicity, and palatability properties. It can be stored and/or dispensed as a liquid, powder, or tablet. Reduction in the most common side effects improves patient compliance and satisfaction. Altered taste profile improves patient compliance and satisfaction. Once formulated it can be used to treat a variety of blood flukes and worms in human and veterinary subjects.